Share This Author
Reporting results of cancer treatment
Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease‐free interval, and reporting results of therapy.
The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy
The study was stopped after analysis of the remission times of 21 pairs of patients, since patients maintained on placebo were treated with 6-MP when relapse occurred, and overall survival was not significantly different for the two treatment programs.
- Chairman., H. Bloom, Estevez, J. Fortner, B. Hoogstraten
- MedicineUICC Current Treatment of Cancer
This series of professional books provides in-depth information on all aspects of the diagnosis and treatment of different hematologic cancers, including clinical evaluation, imaging diagnosis,…
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.
Combinations of effective agents produce at least an additive increase in complete remission rates over that which can be achieved when the agents are used individually, and the toxicity of 6-MP and MTX in combination in patients in remission is additive.
Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells.
- C. Park, M. Amare, M. Savin, J. W. Goodwin, M. Newcomb, B. Hoogstraten
- Medicine, BiologyBlood
- 1 April 1980
An in vitro test system to quantitatively assess the chemotherapy sensitivity of human acute leukemic colony-forming cells in relation to normal granulocytic precursor cells (CFU-C) appears useful in predicting the response of patients to chemotherapy and in the selection of the most effective drugs for use in individual patients.
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
DTIC is currently used in combination with adriamycin in the first-line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.
5‐azacytidine in acute leukemia
101 patients with acute leukemia in relapse were treated with 5‐azacytidine according to three schedules: Regimen A—300 mg/m2(day divided intravenously at 8 hour intervals for 5 days; Regimen B—750…
Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate
It may be concluded therefore that new agents can be effectively studied in patients with "late" disease and responsiveness to drug therapy is maintained as the disease progresses temporally.
Effect of route of administration and effusions on methotrexate pharmacokinetics.
- S. H. Wan, D. Huffman, D. Azarnoff, R. Stephens, B. Hoogstraten
- MedicineCancer research
- 1 December 1974
The plasma concentration profile following the two routes of administration was parallel with a mean final half-life of 24.9 hr, suggesting the presence of malignant effusions could contribute to inter-individual variation in pharmacokinetics.
Daunorubicin in the therapy of acute granulocytic leukemia.
Daunorubicin is an antibiotic of value equal or superior to that of any single drug in the treatment of acute myelocytic leukemia in a variety of concurrently compared schedules of dosage.